Medical companies are experiencing a 'second youth' today on a wave of reports of an increasingly severe coronavirus pandemic in China. According to British research firm Airfinity, the number of coronavirus-related deaths in China is accelerating and has already reached 9,000 cases a day:
The reemergence of the coronavirus pandemic theme has pushed up valuations of Biontech (BNTX.US) and Pfizer (PFE.US) shares, both the first companies to receive Federal Drug Administration (FDA) approval for a vaccine against Covid-19, in the fall of 2020. Moderna (MRNA.US) shares also gained.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app- Novavax shares have been under pressure recently due to the results of a recent study conducted by a group of Australian scientists. They received primary and booster doses of COVID vaccines from Pfizer, Moderna, Novavax and AstraZeneca between March and May of this year. During this period, there was a peak incidence of the Omicron BA.1 and BA.2 variants. The study found that the infection rate, based on PCR testing, was about 49% after the primary dose and 50% after Pfizer's third booster dose. After the baseline dose of Moderna vaccine, the infection rate was 45%, and 48% after the third dose. In contrast, the rate was 53% after the primary dose of Novavax vaccine, and the booster dose unexpectedly increased the rate to 58%. However, the study has not yet been peer-reviewed, and the researchers suggested that further studies be conducted to confirm the results. A potential change in the study's conclusions in favor of Novavax could support a longer recovery in the company's stock. Novavax's vaccine was approved for marketing in Australia in May of this year.
Analysts' consensus is for a 600% increase in the share price from current levels with a maximum target price forecast of $100 and a lowest forecast of $13, potentially representing nearly 30% potential from current levels. Source:TipRanks
Novavax (NVAX.US) chart, D1 interval. The stock has completely erased the gains initiated in March 2020 and landed at the extreme low price levels reached during the covid crash in March 2020. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
